Personalized targeted therapy for lung cancer

International Journal of Molecular Sciences

Volumn 13, Issue 9, 2012, Pages 11471-11496

  Wu, Kehua ^a   House, Larry ^a   Liu, Wanqing ^b   Cho, William C S ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b PURDUE UNIVERSITY   (United States)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

ALK; Biomarker; EGFR; Lung cancer; Next generation sequencing

Indexed keywords

AF 802; AFATINIB; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; AP 26113; ASP 3026; AV 412; BIOLOGICAL MARKER; BMS 690514; CH 5424802; CISPLATIN; CRIZOTINIB; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GSK 1838705A; ICOTINIB; K RAS PROTEIN; LAPATINIB; LDK 378; MAMMALIAN TARGET OF RAPAMYCIN; NERATINIB; NMSE 628; PROTEIN EML4; TUMOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; X 396; XL 647; EGFR PROTEIN, HUMAN; FGFR1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; KRAS PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RAS PROTEIN; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; DRUG EFFICACY; ENZYME ACTIVATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR MODEL; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; REVIEW; SEQUENCE ANALYSIS; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG NEOPLASMS; MORTALITY; PATIENT SELECTION; PROCEDURES; SMALL CELL LUNG CARCINOMA;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; PRECISION MEDICINE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SMALL CELL LUNG CARCINOMA; TOR SERINE-THREONINE KINASES;

EID: 84866940771     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms130911471     Document Type: Review

References (113)

1. Herbst, R.S.; Heymach, J.V.; Lippman, S.M. Lung cancer. N. Engl. J. Med. 2008, 359, 1367-1380.
2. American cancer society. Cancer facts & figures 2011. Available online: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf (accessed on 24 June 2012).
3. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics, 2011. CA. Cancer J. Clin. 2011, 61, 69-90.
4. National Comprehensive Cancer Network. Available online: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (accessed on 10 September 2012).
5. Sequist, L.V.; Lynch, T.J. EGFR tyrosine kinase inhibitors in lung cancer: An evolving story. Annu. Rev. Med. 2008, 59, 429-442.
6. Cagle, P.T.; Chirieac, L.R. Advances in treatment of lung cancer with targeted therapy. Arch. Pathol. Lab. Med. 2012, 136, 504-509.
7. Burgess, D.J. Cancer genetics: Initially complex, always heterogeneous. Nat. Rev. Cancer 2011, 11, 153.
8. Bunnell, C.A.; Shulman, L.N. Will we be able to care for cancer patients in the future? Oncology (Williston Park) 2010, 14, 1343-1348.
9. Hoelder, S.; Clarke, P.A.; Workman, P. Discovery of small molecule cancer drugs: Successes, challenges and opportunities. Mol. Oncol. 2012, 6, 155-176.
10. Prince, A.; Aguirre-Ghizo, J.; Genden, E.; Posner, M.; Sikora, A. Head and neck squamous cell carcinoma: New translational therapies. Mt. Sinai. J. Med. 2010, 77, 684-699.
11. Ballestrero, A.; Garuti, A.; Cirmena, G.; Rocco, I.; Palermo, C.; Nencioni, A.; Scabini, S.; Zoppoli, G.; Parodi, S.; Patrone, F. Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond. Curr. Cancer Drug Targets 2012, 12, 316-328.
12. Ko, A.H.; Tempero, M.A. Personalized medicine for pancreatic cancer: A step in the right direction. Gastroenterology 2009, 136, 43-45.
13. Olopade, O.I.; Grushko, T.A.; Nanda, R.; Huo, D. Advances in breast cancer: Pathways to personalized medicine. Clin. Cancer Res. 2008, 14, 7988-7999.
14. Mitsudomi, T.; Yatabe, Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007, 98, 1817-1824.
15. Sharma, S.V.; Bell, D.W.; Settleman, J.; Haber, D.A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007, 7, 169-181.
16. Ciardiello, F.; Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008, 358, 1160-1174.
17. Scaltriti, M.; Baselga, J. The epidermal growth factor receptor pathway: A model for targeted therapy. Clin. Cancer Res. 2006, 12, 5268-5272.
18. Citri, A.; Yarden, Y. EGF-ERBB signalling: Towards the systems level. Nat. Rev. Mol. Cell Biol. 2006, 7, 505-516.
19. Gazdar, A.F.; Minna, J.D. Deregulated EGFR signaling during lung cancer progression: Mutations, amplicons, and autocrine loops. Cancer Prev. Res. (Phila) 2008, 1, 156-160.
20. Sharma, S.V.; Settleman, J. Oncogenic shock: Turning an activated kinase against the tumor cell. Cell Cycle 2006, 5, 2878-2880.
21. Martine, E.N.; Hahn, M.S.; McKenna, G.W. Molecular Biology and Genetics of Lung Cancer. In Advances in Radiation Oncology in Lung Cancer; Jeremić, B., Ed.; Springer-Verlag Berlin: Heidelberg, Germany, 2005; p. 6.
22. Belani, C.P.; Goss, G.; Blumenschein, G., Jr. Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat. Rev. 2012, 38, 173-184.
23. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
24. Paez, J.G.; Jänne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J. et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
25. Pao, W.; Miller, V.; Zakowski, M.; Doherty, J.; Politi, K.; Sarkaria, I.; Singh, B.; Heelan, R.; Rusch, V.; Fulton, L. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci.USA 2004, 101, 13306-13311.
26. Fukuoka, M.; Wu, Y.L.; Thongprasert, S.; Sunpaweravong, P.; Leong, S.S.; Sriuranpong, V.; Chao, T.Y.; Nakagawa, K.; Chu, D.T.; Saijo, N. et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 2011, 29, 2866-2874.
27. Ulivi, P.; Calistri, D.; Zoli, W.; Amadori, D. Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: New insights and critical aspects. J. Nucleic Acids Investig. 2010, 1, 47-54.
28. Petrelli, F.; Borgonovo, K.; Cabiddu, M.; Barni, S. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: A meta-analysis of 13 randomized trials. Clin. Lung Cancer 2012, 13, 107-114.
29. Mok, T.S. Personalized medicine in lung cancer: What we need to know. Nat. Rev. Clin. Oncol. 2011, 8, 661-668.
30. Keedy, V.L.; Temin, S.; Somerfield, M.R.; Beasley, M.B.; Johnson, D.H.; McShane, L.M.; Milton, D.T.; Strawn, J.R.; Wakelee, H.A.; Giaccone, G. American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol. 2011, 29, 2121-2127.
31. Stella, G.M.; Luisetti, M.; Inghilleri, S.; Cemmi, F.; Scabini, R.; Zorzetto, M.; Pozzi, E. Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies. Respir. Med. 2012, 106, 173-183.
32. Sequist, L.V.; Bell, D.W.; Lynch, T.J.; Haber, D.A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. 2007, 25, 587-595.
33. Cheng, L.; Alexander, R.E.; Maclennan, G.T.; Cummings, O.W.; Montironi, R.; Lopez-Beltran, A.; Cramer, H.M.; Davidson, D.D.; Zhang, S. Molecular pathology of lung cancer: Key to personalized medicine. Mod. Pathol. 2012, 25, 347-369.
34. Shigematsu, H.; Lin, L.; Takahashi, T.; Nomura, M.; Suzuki, M.; Wistuba, I.I.; Fong, M.K.; Lee, H.; Toyooka, S.; Shimizu, N. et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 2005, 97, 339-346.
35. Riely, G.J.; Politi, K.A.; Miller, V.A.; Pao, W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin. Cancer Res. 2006, 12, 7232-7241.
36. Couraud, S.; Zalcman, G.; Milleron, B.; Morin, F.; Souquet, P.J. Lung cancer in never smokers-A review. Eur. J. Cancer 2012, 48, 1299-1311.
37. Yasuda, H.; Kobayashi, S.; Costa, D.B. EGFR exon 20 insertion mutations in non-small-cell lung cancer: Preclinical data and clinical implications. Lancet Oncol. 2012, 13, e23-e31.
38. Ladanyi, M.; Pao, W. Lung adenocarcinoma: Guiding EGFR-targeted therapy and beyond. Mod. Pathol. 2008, 21, S16-S22.
39. Shigematsu, H.; Gazdar, A.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int. J. Cancer 2006, 118, 257-262.
40. Lee, Y.; Shim, H.S.; Park, M.S.; Kim, J.H.; Ha, S.J.; Kim, S.H.; Cho, B.C. High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma. Clin. Cancer Res. 2012, 18, 1760-1768.
41. Hirsch, F.R.; Varella-Garcia, M.; McCoy, J.; West, H.; Xavier, A.C.; Gumerlock, P.; Bunn, P.A., Jr.; Franklin, W.A.; Crowley, J.; Gandara, D.R. et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group study. J. Clin. Oncol. 2005, 23, 6838-6845.
42. Cappuzzo, F.; Hirsch, F.R.; Rossi, E.; Bartolini, S.; Ceresoli, G.L.; Bemis, L.; Haney, J.; Witta, S.; Danenberg, K.; Domenichini, I. et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 2005, 97, 643-655.
43. Sholl, L.M.; Xiao, Y.; Joshi, V.; Yeap, B.Y.; Cioffredi, L.A.; Jackman, D.M.; Lee, C.; Jänne, P.A.; Lindeman, N.I. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am. J. Clin. Pathol. 2010, 133, 922-934.
44. Lee, C.C.; Jia, Y.; Li, N.; Sun, X.; Ng, K.; Ambing, E.; Gao, M.Y.; Hua, S.; Chen, C.; Kim, S. et al. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem. J. 2010, 430, 425-437.
45. Morris, S.W.; Naeve, C.; Mathew, P.; James, P.L.; Kirstein, M.N.; Cui, X.; Witte, D.P. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997, 14, 2175-2188.
46. Scagliotti, G.; Stahel, R.A.; Rosell, R.; Thatcher, N.; Soria, J.C. ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development. Eur. J. Cancer 2012, 48, 961-973.
47. Soda, M.; Choi, Y.L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448, 561-566.
48. Kwak, E.L.; Bang, Y.J.; Camidge, D.R.; Shaw, A.T.; Solomon, B.; Maki, R.G.; Ou, S.H.; Dezube, B.J.; Jänne, P.A.; Costa, D.B. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363, 1693-1703.
49. Chen, J.; Liu, H.; Yang, T.; Wei, S.; Zhou, Q. Clinical significance of the EML4-ALK fusion gene and association with EGFR and KRAS gene mutation in 208 Chinese patients with non-small cell lung cancer. J. Clin. Oncol. 2012, 30, e17514.
50. Sun, Y.; Ren, Y.; Fang, Z.; Li, C.; Fang, R.; Gao, B.; Han, X.; Tian, W.; Pao, W.; Chen, H. et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J. Clin. Oncol. 2010, 28, 4616-4620.
51. Janku, F.; Stewart, D.J.; Kurzrock, R. Targeted therapy in non-small-cell lung cancer-Is it becoming a reality? Nat. Rev. Clin. Oncol. 2010, 7, 401-414.
52. Pao, W.; Girard, N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011, 12, 175-180.
53. Linardou, H.; Dahabreh, I.J.; Kanaloupiti, D.; Siannis, F.; Bafaloukos, D.; Kosmidis, P.; Papadimitriou, C.A.; Murray, S. Assessment of somatic K-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008, 9, 962-972.
54. Pao, W.; Wang, T.Y.; Riely, G.J.; Miller, V.A.; Pan, Q.; Ladanyi, M.; Zakowski, M.F.; Heelan, R.T.; Kris, M.G.; Varmus, H.E. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005, 2, e17.
55. Shepherd, F.A.; Tsao, M.S. Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: A riddle, wrapped in a mystery, inside an enigma. J. Clin. Oncol. 2010, 28, 903-905.
56. Ekman, S.; Wynes, M.W.; Hirsch, F.R. The mTOR pathway in lung cancer and implications for therapy and biomarker analysis. J. Thorac. Oncol. 2012, 7, 947-953.
57. Marti, M.A.; Martinez, P.; Aura, C.; Cedres, S.; Sullivan, I.; Jimenez, J.; Prudkin, L.; Montero, A.M.; Murtra-Garrell, N.; Zamora, E. et al. Amplification of fibroblast growth factor receptor type 1 gene (FGFR1) in samples from 101 NSCLC patients (pts) with squamous cell carcinoma (SCC) histology. J. Clin. Oncol. 2012, 30, abstr7041.
58. Dy, K.G.; Shao, H.; Ho, B.; Yemma, M.; Adjei, A.; Golubovskaya, V.; Cance, V. Preclinical investigation of the antitumor efficacy in lung cancer of Y15, a novel focal adhesion kinase inhibitor. Mol. Cancer Ther. 2011, 10, S1.
59. Hammerman, P.S.; Sos, M.L.; Ramos, A.H.; Xu, C.; Dutt, A.; Zhou, W.; Brace, L.E.; Woods, B.A.; Lin, W.; Zhang, J. et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011, 1, 78-89.
60. Pao, W.; Miller, V.A.; Politi, K.A.; Riely, G.J.; Somwar, R.; Zakowski, M.F.; Kris, M.G.; Varmus, H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2, e73.
61. Ma, C.; Wei, S.; Song, Y. T790M and acquired resistance of EGFR TKI: A literature review of clinical reports. J. Thorac. Dis. 2011, 3, 10-18.
62. Ogawa, T.; Liggett, T.E.; Melnikov, A.A.; Monittom, C.L.; Kusuke, D.; Shiga, K.; Kobayashi, T.; Horii, A.; Chatterjee, A.; Levenson, V.V. et al. Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance. Cell Cycle 2012, 11, 1656-1663.
63. Ghosh, G.; Lian, X.; Kron, S.J.; Palecek, S.P. Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors. BMC Cancer 2012, 12, 95.
64. Choi, Y.L.; Soda, M.; Yamashita, Y.; Ueno, T.; Takashima, J.; Nakajima, T.; Yatabe, Y.; Takeuchi, K.; Hamada, T.; Haruta, H. et al. ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 2010, 363, 1734-1739.
65. Sequist, L.V.; Waltman, B.A.; Dias-Santagata, D.; Digumarthy, S.; Turke, A.B.; Fidias, P.; Bergethon, K.; Shaw, A.T.; Gettinger, S.; Cosper, A.K. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011, 3, doi: 10.1126/scitranslmed.3002003.
66. Gefitinib (marketed as Iressa) Information. Available online: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm110473.htm (accessed on 07 July 2012).
67. Thatcher, N.; Chang, A.; Parikh, P.; Rodrigues Pereira, J.; Ciuleanu, T.; von Pawel, J.; Thongprasert, S.; Tan, E.H.; Pemberton, K.; Archer, V. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366, 1527-1537.
68. Metro, G.; Crinò, L. Advances on EGFR mutation for lung cancer. Transl. Lung Cancer Res. 2012, 1, 5-13.
69. Kim, Y.; Ko, J.; Cui, Z.; Abolhoda, A.; Ahn, J.S.; Ou, S.H.; Ahn, M.J.; Park, K. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol. Cancer Ther. 2012, 11, 784-791.
70. Boyer, J.M.; Blackhall, H.F.; Park, K.; Barrios, H.C.; Krzakowski, J.M.; Taylor, I.; Liang, Q.J.; Denis, J.L.; O'Connell, P.J.; Ramalingam, S.S. Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT). J. Clin. Oncol. 2010, 28, 18s.
71. ARIAD. Available online: http://www.ariad.com/wt/tertiarypage/alk_inhibitor (accessed on 24 June 2012).
72. Mehra, R.; Camidge, D.R.; Sharma, S.; Felip, E.; Tan, D.S.; Vansteenkiste, J.F.; de Pas, T.M.; Kim, D.W.; Santoro, A.; Liu, G. et al. First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors. J. Clin. Oncol. 2012, 30, abstr 3007.
73. Rizvi, A.N.; Pao, W.; Kris, G.M.; Rusch, V.; Ladanyi, M.; Ginex, K.P.; Zakowski, F.M.; Tyson, B.L.; Heelan, T.R.; Varmus, H. A prospective study to correlate EGFR mutations with gefitinib response. J. Clin. Oncol. 2005, 23, abstr7091.
74. Milella, M.; Nuzzo, C.; Bria, E.; Sperduti, I.; Visca, P.; Buttitta, F.; Antoniani, B.; Merola, R.; Gelibter, A.; Cuppone, F. et al. EGFR molecular profiling in advanced NSCLC: A prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. J. Thorac. Oncol. 2012, 7, 672-680.
75. Kim, E.S.; Herbst, R.S.; Wistuba, I.I.; Lee, J.J.; Blumenschein, G.R., Jr.; Tsao, A.; Stewart, D.J.; Hicks, M.E.; Erasmus, J., Jr.; Gupta, S. et al. The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discov. 2011, 1, 44-53.
76. Rosell, R.; Carcereny, E.; Gervais, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Palmero, R.; Garcia-Gomez, R.; Pallares, C.; Sanchez, J.M. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13, 239-246.
77. Zhou, C.; Wu, Y.L.; Chen, G.; Feng, J.; Liu, X.Q.; Wang, C.; Zhang, S.; Wang, J.; Zhou, S.; Ren, S. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011, 12, 735-742.
78. Mitsudomi, T.; Morita, S.; Yatabe, Y.; Negoro, S.; Okamoto, I.; Tsurutani, J.; Seto, T.; Satouchi, M.; Tada, H.; Hirashima, T. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol. 2010, 11, 121-128.
79. Yang, C.J.; Schuler, H.M.; Yamamoto, N.; O'Byrne, J.K.; Hirsh, V.; Mok, T.; Geater, L.S.; Orlov, V.S.; Tsai, C.; Boyer, J.M. et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J. Clin. Oncol. 2012, 30, LBA7500.
80. Inoue, A.; Kobayashi, K.; Maemondo, M.; Sugawara, S.; Oizumi, S.; Isobe, H.; Gemma, A.; Saijo, Y.; Yoshizawa, H.; Morita, S. et al. Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. J. Clin. Oncol. 2011, 29, abstr 7519.
81. Kim, D.W.; Lee, S.H.; Lee, J.S.; Lee, M.A.; Kang, J.H.; Kim, S.Y.; Shin, S.W.; Kim, H.K.; Heo, D.S. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. Lung Cancer 2011, 71, 65-69.
82. Tamura, K.; Okamoto, I.; Kashii, T.; Negoro, S.; Hirashima, T.; Kudoh, S.; Ichinose, Y.; Ebi, N.; Shibata, K.; Nishimura, T. et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: Results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br. J. Cancer. 2008, 98, 907-914.
83. Sequist, L.V.; Martins, R.G.; Spigel, D.; Grunberg, S.M.; Spira, A.; Jänne, P.A.; Joshi, V.A.; McCollum, D.; Evans, T.L.; Muzikansky, A. et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 2008, 26, 2442-2449.
84. Inoue, A.; Kobayashi, K.; Usui, K.; Maemondo, M.; Okinaga, S.; Mikami, I.; Ando, M.; Yamazaki, K.; Saijo, Y.; Gemma, A. et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J. Clin. Oncol. 2009, 27, 1394-1400.
85. Sugio, K.; Uramoto, H.; Onitsuka, T.; Mizukami, M.; Ichiki, Y.; Sugaya, M.; Yasuda, M.; Takenoyama, M.; Oyama, T.; Hanagiri, T. et al. Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer 2009, 64, 314-318.
86. Han, B.; Xiong, L.; Sun, J.; Li, R.; Lou, Y.; Zhang, Y. Erlotinib as neoadjuvant treatment in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation (NCT01217619, ESTERN). J. Clin. Oncol. 2012, 30, abstr e17551.
87. Yang, J.C.; Shih, J.Y.; Su, W.C.; Hsia, T.C.; Tsai, C.M.; Ou, S.H.; Yu, C.J.; Chang, G.C.; Ho, C.L.; Sequist, L.V. et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase II trial. Lancet Oncol. 2012, 13, 539-548.
88. Kris, G.M.; Mok, T.; Ou, S.H.; Martins, R.; Kim, W.D.; Goldberg, Z.; Zhang, H.; Taylor, I.; Letrent, P.S.; Janne, A.P. First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers. J. Clin. Oncol. 2012, 30, abstr 7530.
89. Zhong, W.; Yang, X.; Liao, R.; Nie, Q.; Dong, S.; Su, J.; Zhang, X.; Zhou, Q.; Yang, J.; Wu, L.Y. Induction erlotinib or gemcitabine/carboplatin factorial assignment therapy in stage IIIA-N2 non-small cell lung cancer. J. Clin. Oncol. 2011, 29, abstr e17512.
90. Rosell, R.; Perez-Roca, L.; Sanchez, J.J.; Cobo, M.; Moran, T.; Chaib, I.; Provencio, M.; Domine, M.; Sala, M.A.; Jimenez, U. et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009, 4, e5133.
91. Pietanza, M.C.; Gadgeel, S.M.; Dowlati, A.; Lynch, T.J.; Salgia, R.; Rowland, K.M., Jr.; Wertheim, M.S.; Price, K.A.; Riely, G.J.; Azzoli, C.G. et al. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. J. Thorac. Oncol. 2012, 7, 856-865.
92. Sequist, L.V.; Besse, B.; Lynch, T.J.; Miller, V.A.; Wong, K.K.; Gitlitz, B.; Eaton, K.; Zacharchuk, C.; Freyman, A.; Powell, C. et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28, 3076-3083.
93. Sorlini, C.; Barni, S.; Petrelli, F.; Novello, S.; de Marinis, F.; de Pas, M.T.; Grossi, F.; Bearz, A.; Mencoboni, M.; Aieta, M. et al. PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2011, 29, abstr TPS214.
94. Hisamoto, A.; Sasaki, J.; Takigawa, N.; Shioyama, Y.; Kishimoto, J.; Takemoto, M.; Hotta, K.; Tanimoto, M.; Ichinose, Y.; Kiura, K. et al. A phase II trial of induction gefitinib monotherapy followed by cisplatin-docetaxel and concurrent thoracic irradiation in patients with EGFR-mutant locally advanced non-small-cell lung cancer (LA-NSCLC): LOGIK0902/OLCSG0905 intergroup trial. J. Clin. Oncol. 2012, 30, abstr 7045.
95. Kobayashi, T.; Koizumi, T.; Agatsuma, T.; Yasuo, M.; Tsushima, K.; Kubo, K.; Eda, S.; Kuraishi, H.; Koyama, S.; Hachiya, T. et al. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol. 2012, 69, 1241-1246.
96. Matsuura, S.; Inui, N.; Ozawa, Y.; Nakamura, Y.; Toyoshima, M.; Yasuda, K.; Yamada, T.; Shirai, T.; Suganuma, H.; Yokomura, K. et al. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations. Jpn. J. Clin. Oncol. 2011, 41, 959-963.
97. Yoshioka, H.; Hotta, K.; Kiura, K.; Takigawa, N.; Hayashi, H.; Harita, S.; Kuyama, S.; Segawa, Y.; Kamei, H.; Umemura, S. et al. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J. Thorac. Oncol. 2010, 5, 99-104.
98. Garassino, C.M.; Martelli, O.; Bettini, A.; Floriani, I.; Copreni, E.; Lauricella, C.; Ganzinelli, M.; Marabese, M.; Broggini, M.; Veronese, S. et al. TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. J. Clin. Oncol. 2012, 30, abstr LBA7501.
99. Metro, G.; Chiari, R.; Duranti, S.; Siggillino, A.; Fischer, M.J.; Giannarelli, D.; Ludovini, V.; Bennati, C.; Marcomigni, L.; Baldi, A. et al. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. Lung Cancer, 2012, in press.
100. Mok, T.S.; Wu, Y.L.; Thongprasert, S.; Yang, C.H.; Chu, D.T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361, 947-957.
101. Zhu, C.Q.; da Cunha Santos, G.; Ding, K.; Sakurada, A.; Cutz, J.C.; Liu, N.; Zhang, T.; Marrano, P.; Whitehead, M.; Squire, J.A. et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol. 2008, 26, 4268-4275.
102. Janne, A.P.; Shaw, T.A.; Pereira, J.R.; Jeannin, G.; Vansteenkiste, J.; Barrios, H.C.; Franke, A.F.; Grinsted, L.; Smith, D.P.; Zazulina, V. et al. Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2012, 30, abstr 7503.
103. Riely, J.G.; Brahmer, R.J.; Planchard, D.; Crinò, L.; Doebele, C.R.; Mas Lopez, L.; Gettinger, N.S.; Schumann, C.; Li, X.; Atkins B.M. et al. A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. J. Clin. Oncol. 2012, 30, abstr 7531.
104. Crinò, L.; Kim, D.; Riely, J.G.; Janne, A.P.; Blackhall, H.F.; Camidge, R.D.; Hirsh, V.; Mok, T.; Solomon, J.B.; Park, K. et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J. Clin. Oncol. 2011, 29, abstr 7514.
105. Kim, D.W.; Ahn, M.J.; Shi, Y.; De Pas, T.M.; Yang, P.C.; Riely, J.G.; Crinò, L.; Evans, L.T.; Liu, X.; Han, J.Y. et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2012, 30, abstr 7533.
106. Shaw, A.T.; Yeap, B.Y.; Solomon, B.J.; Riely, G.J.; Gainor, J.; Engelman, J.A.; Shapiro, G.I.; Costa, D.B.; Ou, S.H.; Butaney, M. et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol. 2011, 12, 1004-1012.
107. Cho, W.; Ziogas, D.E.; Katsios, C.; Roukos, D.H. Emerging personalized oncology: Sequencing and systems strategies. Futur. Oncol. 2012, 8, 637-641.
108. Daniels, M.; Goh, F.; Wright, C.M.; Sriram, K.B.; Relan, V.; Clarke, B.E.; Duhig, E.E.; Bowman, R.V.; Yang, I.A.; Fong, K.M. et al. Whole genome sequencing for lung cancer. J. Thorac. Dis. 2012, 4, 155-163.
109. Govindan, R.; Hammerman, S.P.; Hayes, N.D.; Wilkerson, D.M.; Baylin, S.; Meyerson, M.; Comprehensive genomic characterization of squamous cell carcinoma of the lung. J. Clin. Oncol. 2012, 30, abstr 7006.
110. Lee, W.; Jiang, Z.; Liu, J.; Haverty, P.M.; Guan, Y.; Stinson, J.; Yue, P.; Zhang, Y.; Pant, K.P.; Bhatt, D. et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010, 465, 473-477.
111. Ju, Y.S.; Lee, W.C.; Shin, J.Y.; Lee, S.; Bleazard, M.T.; Won, J.K.; Kim, Y.T.; Kim, J.I.; Kang, J.H.; Seo, J.S. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012, 22, 436-445.
112. Belvedere, O.; Berri, S.; Chalkley, R.; Conway, C.; Barbone, F.; Pisa, F.; MacLennan, K.; Daly, C.; Alsop, M.; Morgan, J. et al. A computational index derived from whole-genome copy number analysis is a novel tool for prognosis in early stage lung squamous cell carcinoma. Genomics 2012, 99, 18-24.
113. Tran, B.; Dancey, J.E.; Kamel-Reid, S.; McPherson, J.D.; Bedard, P.L.; Brown, A.M.; Zhang, T.; Shaw, P.; Onetto, N.; Stein, L. et al. Cancer genomics: Technology, discovery, and translation. J. Clin. Oncol. 2012, 30, 647-660.